Drug intelligence / Profile preview

interferon alfa-5

Development stage
Phase 2
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
None
01

Overview

Interferon alfa-5 is one of the naturally occurring subtypes of human interferon alpha (IFN-α), a type I interferon cytokine involved in the innate immune response to viral infections. Interferons are produced by leukocytes and play a key role in antiviral defense, immunomodulation, and inhibition of cell proliferation. While pharmaceutical products such as "interferon alfa" or "Multiferon" contain mixtures of several IFN-α subtypes (including but not limited to IFNA1, IFNA2, and others), specific information on clinical use or commercial availability for the isolated subtype "interferon alfa-5" is not available. The mechanism of action for all type I interferons involves binding to the interferon alpha/beta receptor complex (IFNAR1/IFNAR2) on cell surfaces, leading to activation of intracellular signaling pathways that upregulate antiviral proteins and modulate immune responses[1][2]. There is no evidence that pure recombinant or natural "interferon alfa-5" alone has been developed as an approved drug; it may be present as a component in multi-subtype preparations.

Other names
IFN-alpha 5IFN-alpha5IFN-alpha-5IFNA5IFNA-5IFNA 5interferon alpha-5
02

Targets

IFNAR1 (Interferon alpha/beta receptor 1)

Beyond the preview

Go deeper on interferon alfa-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alfa-5.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call